<DOC>
	<DOCNO>NCT00477919</DOCNO>
	<brief_summary>RATIONALE : A hand hold electronic tool use monitor symptom assess quality life may improve communication patient doctor improve ability plan treatment patient advance cancer receive palliative care . It yet know whether symptom well control without use electronic tool . PURPOSE : This randomized phase III trial study electronic tool see well record cancer symptoms patient advanced cancer receive palliative care .</brief_summary>
	<brief_title>E-MOSAIC Electronic Tool Monitor Symptoms</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect electronic tool monitoring symptom syndromes associate advanced cancer ( E-MOSAIC ) Longitudinal Monitoring Sheet ( LoMoS ) global quality life ( G-QOL ) patient advance incurable cancer receive palliative anticancer treatment . Secondary - Determine tool affect communication patient treat physician . - Determine tool affect symptoms syndromes reported patient . - Determine tool impact symptom management performance . Tertiary - Identify factor influence change G-QOL . - Determine patient adapt illness burden treatment . - Describe patient ' decision-making preference . OUTLINE : This control , randomize , longitudinal , multicenter study . Physicians stratify accord participate center . Physicians randomize 1 2 arm . All patient allocate physician undergo intervention . - Arm I : Patients complete weekly symptom assessment nutritional intake use Palm-based monitoring tool . Nurses record weight Karnofsky performance status ( KPS ) score weekly . A proof electronic transfer sheet print store . - Arm II : Patients complete weekly assessment comprise visual analogue scale ( VAS ) pain , fatigue , drowsiness , nausea , anxiety , depression , shortness breath , loss appetite , overall well-being ; 3 optional symptom select patient ; estimate nutritional intake use electronic tool monitoring symptom syndromes associate advanced cancer ( E-MOSAIC ) . Nurses record patient 's weight , KPS score , body mass index , assessment current medication pain ( i.e. , morphine-equivalent daily dose ) , fatigue , anorexia/cachexia syndrome weekly . A Longitudinal Monitoring Sheet ( LoMoS ) print ( comprise VAS pain , pain medication , fatigue , KPS , medication fatigue [ i.e. , methylphenidate hydrochloride epoetin alfa ] , anorexia , weight change , nutritional intake , medication , supplement , counsel anorexia , VAS individually select symptom ) store . In arm , patient assess outcome criterion baseline week 3 6 ( end study ) . PROJECTED ACCRUAL : A total 24 physician 192 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance incurable cancer Symptomatic disease , define meeting ≥ 1 follow criterion : Pain Visual Analogue Scale ( VAS ) ≥ 3/10 and/or morphine equivalent daily dose ≥ 10 mg ≥ 3 day Anorexia VAS ≥ 3/10 and/or weight loss ≥ 2 % 2 month ≥ 5 % 6 month Fatigue VAS ≥ 3/10 and/or Karnofsky performance status &lt; 70 % Depression anxiety VAS ≥ 3/10 and/or treatment antidepressant ≥ 5 day plan ≥ 1 month Receiving continuously , weekly , biweekly palliative anticancer treatment meet 1 follow criterion : At least 1 firstline treatment follow : Metastatic melanoma Renal cell cancer Pancreatic cancer Biliary tract cancer Mesothelioma Prostate cancer ( chemotherapy ) Advanced glioblastoma At least 1 secondline treatment follow : Extensive stage small cell lung cancer Stage IV nonsmall cell lung cancer Colorectal cancer Gastric cancer Esophageal cancer Bladder cancer Sarcoma Carcinoma unknown primary At least 1 thirdline chemotherapy regimen follow : Metastatic breast cancer Ovarian cancer Anticancer treatment must give outpatient setting , within clinical trial , weekly monitoring , expect tumor response rate ≤ 20 % accord literature No testicular cancer No hematological malignancy No primary brain tumor glioblastoma Physician characteristic : No change standard care symptom assessment major communication skill strategy within past 3 month Experienced medical oncology ( i.e. , work ≥ 50 % clinical oncology within past 24 month ) Likely stay participate institution time require treat ≥ 5 study patient Able independently communicate patient aspect cancer care Able independently perform immediate change intervention patient care without institutional requirement counsel another colleague prescribing ( i.e. , symptom control ) Completed basic communication skill course equivalent training ( i.e. , familiar communication skill ) PATIENT CHARACTERISTICS : Able understand assessment instrument language Able understand physician communication without difficulty ( i.e. , due culture , language , speech ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>fatigue</keyword>
	<keyword>anorexia</keyword>
	<keyword>cachexia</keyword>
	<keyword>pain</keyword>
	<keyword>weight change</keyword>
	<keyword>depression</keyword>
	<keyword>poor performance status</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>